Antihypertensive medicine use differs between Ghana and Nigeria

Samantha A. Hollingworth1,2*, Daniel Ankrah3, Benjamin S. C. Uzochukwu4, Chinyere C. Okeke4, Francis Ruiz5 and Emily Thacher6

Abstract

Background: Non-communicable diseases are a growing burden in many African countries; cardiovascular disease is the main disease. Antihypertensive medicines (AHM) are a common treatment option but we know little about community use in most low- and medium-income countries (LMIC). We aimed to describe the use of antihypertensive medicines (AHM) in Ghana and Nigeria using a novel data source.

Methods: We used data from mPharma—a health and pharmaceutical company which distributes pharmaceuticals to hospital and retail pharmacies. We extracted data using the anatomical therapeutic chemical (ATC) classification codes and calculated use in defined daily doses and explored patterns by class, medicines, dose, and originator or generic product.

Results: AHM use differed between Ghana and Nigeria. The most used classes in Ghana were angiotensin receptor blockers (ARB) followed by calcium channel blockers (CCB) and angiotensin-converting-enzyme inhibitors (ACEi). The five most used products were 16 mg candesartan, 30 mg nifedipine, 10 mg lisinopril, 5 mg amlodipine and 50 mg losartan. In Nigeria ARB, CCB and diuretics were widely used; the top five products were 50 mg losartan, 10 mg lisinopril, 30 mg nifedipine, 40 mg furosemide, and 5 mg amlodipine. More originator products were used in Ghana than Nigeria.

Conclusion: The differences between Ghana and Nigeria may result from a combination of medical, contextual and policy evidence and reflect factors related to clinical guidance (e.g. standard treatment guidelines), accessibility to prescribers and the role of community pharmacies, and structure of the health system and universal health coverage including funding for medicines. We show the feasibility of using novel data sources to gain insights on medicines use in the community.

Keywords: Antihypertensive medicines, Hypertension, Ghana, Nigeria, Pharmacoepidemiology, (PubMed MESH terms)

Background

Non-communicable diseases (NCD) are the leading public health challenges globally in the twenty-first century resulting in ill health and death, economic loss, diminished quality of life, and poor social development in both high- and low-resourced countries [1, 2]. In the latter, NCDs are growing swiftly; 41 million people die each year (i.e. 71% of all deaths globally). Each year, more than 15 million people aged between 30 and 69 die from a NCD where 85% of these so-called ‘premature’ deaths occur in low-resourced countries [3]. Four NCDs account for most (> 80%) premature NCD deaths: cardiovascular diseases (CVD 17.9 million deaths annually) is...
double that of the next group with most deaths i.e. cancers (9.0 million) with substantial burdens from respiratory diseases (3.9 million), and diabetes (1.6 million) [4].

Hypertension—untreated or uncontrolled—is the single largest contributor to CVD causing stroke, heart failure, and coronary artery disease; it is also a major contributor to kidney disease [5].

Most guidelines recommend that hypertension is diagnosed when a person’s systolic blood pressure (SBP) in the office or clinic is ≥140 mm Hg and or their diastolic blood pressure (DBP) is ≥90 mm Hg following repeated examination [6].

Africa represents almost half of all people with high blood pressure in the world (46%) exceeding the proportion of deaths in low-resourced countries (40%) [7]. The overall prevalence of hypertension in Nigeria ranges from 8 to 46% depending on the study target population, type of measurement, and threshold value for defining hypertension [8, 9]. The prevalence is similar in men and women (7.9–50.2% vs. 3.5–68.8%, respectively) and in the urban (8.1–42.0%) and rural setting (13.5–46.4%). The pooled prevalence increased from 8.6% in the only study in the 1970s (1970–1979) to 22.5% (2000–2011) [9]. It also varies across the geo-political zones [10]. In Ghana the pooled prevalence of hypertension from a recent meta-analysis was 27.0% (95% CI 24.0–30.0%); it was double in the southern coastal (28%, 95% CI 24.0–31.0%) and middle geo-ecological areas (29%, 95% CI 25.0–33.0%) compared to the northern areas (13%, 95% CI 7.0–21.0%) [11].

For countries with constrained health budgets, every effort needs to be made to reduce patients’ reliance on costly medical treatments, including for NCDs, for which medicines are often the mainstay of treatment to reduce associated morbidity and premature mortality [12–14]. The two main treatment approaches for hypertension are lifestyle modifications (more fruits and vegetables, less fatty food, less salt, more exercise exercise) and antihypertensive medicines (AHM) comprising several therapeutic groups.

There are several studies of hypertension in Ghana [15] and Nigeria but few on the use of AHM; most are confined to hospital audits [16], with one considering community use [17]. We aimed to describe the community use of antihypertensive medicines in Ghana and Nigeria using a novel data source.

Methods
Data sources
We used data from mPharma (https://mpharma.com/)—a health and pharmaceutical company based in Accra, Ghana. They distribute pharmaceuticals to hospitals and retail pharmacies and have aggregated data on distributed medicines. This study was granted exemption from ethics review by the University of Queensland, Australia (Ref no 2020000453, 4 March 2020). The research uses only existing collections of data that contain only non-identifiable data and is of negligible risk. The parties (SH, University of Queensland) and mPharma (ET) signed a non-disclosure agreement due to the commercial nature of the data. Only mPharma employees had access to the raw data, while SH analysed the de-identifiable data extracted at aggregated level.

Data analysis
The data were extracted based on the Anatomical Therapeutic Chemical (ATC) classification codes [18] of antihypertensive medicines. These included antihypertensives (C02), diuretics (C03), peripheral vasodilators (C04), vasoprotectives (C05) beta blocking agents (C07), calcium channel blockers (C08) and agents acting on the renin-angiotensin system (C09). Each product was noted for its medicine class (e.g. a calcium channel blockers) medicine (e.g. amlodipine) and dose formulation (e.g. 5 mg tablets). The medicine classes included: centrally-acting adrenergic agent (AAC); peripherally-acting adrenergic agent (AAP); alpha adrenergic blocker (AB); angiotensin converting enzyme inhibitor (ACEi); angiotensin receptor blocker (ARB); beta blocker (BB); calcium channel blocker (CCB); diuretic (DU); and statin (ST in combination products). We excluded the use of hydralazine because it is not used as a first line medicine and only used for hypertensive emergencies where labetalol is contraindicated. We extracted data on sales volume for each month between 1 January 2016 to 31 October 2020.

To standardise the amount of drug dispensed, we used the defined daily dose (DDD) metric from the WHO Collaborating Centre for Drug Statistics Methodology [18]. This DDD is the average daily maintenance dose for a typical 70 kg adult when used for its main indication. The DDD is useful for comparing medicines use across patient populations and accounts for dose formulation (e.g. tablets and capsules) and quantity within a regular pack (e.g. 28 tablets). We calculated the DDD use using a modified formula: [N (dispensed prescriptions) × M (mass of dose) × Q (quantity of pack size)]/DDD.

We examined the data by country (Ghana and Nigeria), medicine class (e.g. calcium channel blockers, CCB), medicine (e.g. nifedipine), dose (e.g. 5 mg), and product type (originator brand or generic). We descriptively analysed the data using Microsoft Office Excel for Office 365.

Results
Use by class
AHM use differed between Ghana and Nigeria. The most used single-medicine classes in Ghana were ARB
(39.2%) followed by CCB (32.1%), and ACEi (13.4%, Table 1). There was low use of diuretics (7.5%) and BB (6.7%). In Nigeria, however, the most used classes were ARB (26.7%), CCB (22.8%), diuretics (18.5%) and ACEi (14.6%, Table 1). In Ghana, single-medicine products were preferred (99.4% of total) than Nigeria (92.3% of total). Three single-class groups accounted for 84.7% of all use in Ghana (ARB, CCB and ACEi) and 68.0% of all use in Nigeria (ARB, CCB, DU).

The use of combination-class products was over tenfold higher in Nigeria (7.7%) than Ghana (0.6%, Table 1). There were only two combination classes used in Ghana: a CCB plus a statin (94.4% of all combination use) and BB plus diuretic (remaining 5.6% of all combination use). In Nigeria, combination products accounted for 7.7% of all class products used; one class group—a double diuretics combination i.e. amiloride plus hydrochlorothiazide—accounted for four fifths (80.9%) of all combination use. There was some use of a CCB + ARB + diuretic (10.2% of combination use; amiodipine plus valsartan plus hydrochlorothiazide), CCB + ARB (4.6 of all combination use; amiodipine plus telmisartan), and BB plus a diuretic (3.9% of all combination use; atenolol plus chlorothalidone, Table 1). The least used combination products included a CCB + statin (amiodipine plus atorvastatin), and ACEi + ARB (ramipril + felodipine, Table 1).

### Use by medicine

The five most used medicines in Ghana were candesartan, nifedipine, lisinopril, amloidipine, and losartan accounting for 79% of the top ten medicines (Table 2). The five most used medicines in Nigeria were losartan, lisinopril, nifedipine, furosemide, and amloidipine accounting for 74% of the top ten medicines (Table 2).

The most widely used ARB in Ghana was candesartan (68.6 of all ARB) followed by losartan (24.3% of all ARB). Conversely, in Nigeria, losartan accounted for more than half of use (55.1% of all ARB) followed by valsartan (25.5% of all ARB) and telmisartan (15.7% of all ARB). Of the CCB used in Ghana, nifedipine was the most widely used (51.7% of all CCB) followed by amloidipine (32.8%) and furosemide (15.6%, Table 2). In Nigeria two CCBs were used almost exclusively: nifedipine (50.8% of all CCB) and amloidipine (49.1%, Table 2). In both Ghana and Nigeria the most commonly-used ACEi was lisinopril (99.4% of all ACEi in Ghana, 81.3% in Nigeria) and ramipril (0.6% of all ACEi in Ghana, 17.3% in Nigeria, Table 2).

The use of diuretics was substantially different across the two countries. The preferred medicines in Ghana were indapamide (90.4% of all DU), bendroflumethiazide (6.9% of all DU) and furosemide (2.7% of all DU, Table 2) whereas in Nigeria, the preferred DUs were furosemide (61.2% of all DU), hydrochlorothiazide (22.8% of all DU), and indapamide (11.4% of all DU, Table 2). In Ghana, three medicines accounted for most BB use: carvedilol (44.8% of all BB), atenolol (41.0% of all BB); and metoprolol (12.1% of all BB) but the pattern was different in Nigeria where the most widely used BBS were atenolol (57.5% of all BB), metoprolol (19.3% of all BB), and carvedilol (10.6% of all BB, Table 2).

### Use by dose formulation

In Ghana, the five most used single-medicine dose products were candesartan 16 mg (16.0% of all single product use), nifedipine 30 mg (12.4%), amloidipine 5 mg (10.6%, only dose used), candesartan 8 mg (8.7%), and losartan 50 mg (7.8%, Table 3). The top ten medicine dose products constituted 80.5% of all single medicine products used. In Nigeria, the five most used single-medicine dose products were furosemide 40 mg (12.2% of all single product use), amloidipine 5 mg (12.1%, only dose used), losartan 50 mg (8.3%), nifedipine 30 mg (8.2%), and lisinopril 10 mg (7.2%, Table 3). The top ten medicine dose products constituted 71.6% of all single medicine products used.

### Table 1

Use of antihypertensive medicines by class (defined daily dose [DDD] and proportion [%]) for single and combination products in Ghana and Nigeria

| Class | Ghana Use (DDD) | Ghana % | Nigeria Use (DDD) | Nigeria % |
|-------|-----------------|---------|-------------------|-----------|
| Single |                |         |                   |           |
| ARB   | 380,029         | 39.2    | 940,546           | 26.7      |
| CCB   | 310,645         | 32.1    | 803,845           | 22.8      |
| ACEi  | 129,783         | 13.4    | 514,422           | 14.6      |
| DU    | 72,272          | 7.5     | 651,408           | 18.5      |
| BB    | 65,393          | 6.7     | 211,322           | 6.0       |
| AAC   | 4,528           | 0.5     | 107,321           | 3.0       |
| AAP   | –               | 0       | 23,466            | 0.7       |
| Total | 962,650         | 99.4    | 3,252,329         | 92.3      |
| Combination |     |         |                   |           |
| DU + DU | 0            | 0       | 218,619           | 6.2       |
| BB + DU | 342          | 0.0     | 10,421            | 0.3       |
| CCB + ARB | 0           | 0       | 12,360            | 0.4       |
| CCB + ARB + DU | 0     | 0       | 27,665            | 1.3       |
| CCB + ST | 5813        | 0.6    | 1290              | 0.0       |
| ACEi + ARB | 2          | 0       |                   | 0.0       |
| Total | 6155           | 0.6    | 270,357           | 7.7       |

**AR** Angiotensin receptor blockers, **CCB** calcium channel blocker, **ACE** angiotensin-converting enzyme inhibitor, **BB** beta-blocker, **DU** Diuretic, **AAP** Angiotensin, **AAC** and ST are not conventional abbreviations. AAC will involve centrally acting drugs like methyldopa
The use of generic products (across all single and combination class products) dominated in Nigeria (78.4%) but they were less often used in Ghana (21.6%; data not shown).

The use of generic products for the five main classes of single products dominated in Nigeria (average 94.3%) but they were less often used in Ghana (average 30.8%). The proportional use of generic ARBs was 90.3% in Nigeria but only 24.5% in Ghana—a difference of almost four-fold; the proportional use of diuretics in Nigeria (88.1%) was nine times that of Ghana (9.6%, Table 4). The use of CCB in Nigeria was almost exclusively generic (97.9%) but lower in Ghana (59.4%). In four classes—BB, ARB, ACEi, and diuretics—the use of originator brands prevailed in Ghana whereas the use of generic products dominated in all five classes in Nigeria (Table 4).

### Discussion

Dispensed use of antihypertensives varied between Ghana and Nigeria. The most used medicine class in Ghana was ARB followed by CCB and ACEi. The five

### Table 2 Use of antihypertensive medicines by medicines (defined daily dose [DDD] and proportion within class [%]) for single products in Ghana and Nigeria plus top ten ranking and proportion

| Class | Medicine | Ghana (Use DDD) | % within class | Rank | % of top 10 | Nigeria (Use DDD) | % within class | Rank | % of top 10 |
|-------|----------|-----------------|----------------|------|-------------|-------------------|----------------|------|-------------|
| ARB   | Candesartan | 260,561         | 68.6%          | 1    | 27.7%       | 33,203            | 3.5%           |      |             |
|       | Losartan  | 92,384          | 24.3%          | 5    | 9.8%        | 517,910           | 55.1%          | 1    | 17.8%       |
|       | Valsartan | 27,084          | 7.1%           | 9    | 2.9%        | 239,830           | 25.5%          | 6    | 8.3%        |
|       | Telmisartan | 0              |                 |      |             | 147,807           | 15.7%          | 8    | 5.1%        |
|       | Irbesartan | 0              |                 |      |             | 1796             | 0.2%           |      |             |
|       | Total     | 380,029         |                 |      |             | 940,546           |                |      |             |
| CCB   | Nifedipine | 160,490         | 51.7%          | 2    | 17.1%       | 408,500           | 50.8%          | 3    | 14.1%       |
|       | Amlodipine | 101,778         | 32.8%          | 4    | 10.8%       | 394,731           | 49.1%          | 5    | 13.6%       |
|       | Felodipine | 48,377          | 15.6%          | 7    | 5.1%        | 600              | 0.1%           |      |             |
|       | Nimodipine | 0              |                 |      |             | 15               | 0.0%           |      |             |
|       | Total     | 310,645         |                 |      |             | 803,845           |                |      |             |
| ACEi  | Lisinopril | 129,004         | 99.4%          | 3    | 13.7%       | 418,073           | 81.3%          | 2    | 14.4%       |
|       | Ramipril  | 779             | 0.6%           |      |             | 88,831            | 17.3%          |      |             |
|       | Perindopril | 0              | 0.0%           |      |             | 7170             | 1.4%           |      |             |
|       | Captopril | 18              | 0.0%           |      |             | 178              | 0.0%           |      |             |
|       | Enalapril | 170             | 0.0%           |      |             | 170              | 0.0%           |      |             |
|       | Total     | 129,783         |                 |      |             | 514,422           |                |      |             |
| DU    | Indapamide | 65,332          | 90.4%          | 6    | 6.9%        | 74,382            | 11.4%          |      |             |
|       | Furosemide | 1968            | 2.7%           |      |             | 398,932           | 61.2%          | 4    | 13.7%       |
|       | Hydrochlorothiazide | 0 | 0.0% |      |             | 148,244           | 22.8%          | 7a  | 5.1%        |
|       | Bendroflumethiazide | 4972 | 6.9% |      |             | 21,731            | 3.3%           |      |             |
|       | Metolazone | 0              | 0.0%           |      |             | 5202             | 0.8%           |      |             |
|       | Torasemide | 0              | 0.0%           |      |             | 2917             | 0.4%           |      |             |
|       | Total     | 72,272          |                 |      |             | 651,408           |                |      |             |
| BB    | Atenolol  | 26,810          | 41.0%          | 10   | 2.8%        | 121,556           | 57.5%          | 9    | 4.2%        |
|       | Carvedilol | 29,275          | 44.8%          | 8    | 3.0%        | 22,484            | 10.6%          | 6    | 8.7%        |
|       | Metoprolol | 7911            | 12.1%          |      |             | 40,816            | 19.3%          |      |             |
|       | Propanolol | 21              | 0.0%           |      |             | 11,274            | 5.3%           |      |             |
|       | Bisoprolol | 1377            | 2.1%           |      |             | 7016              | 3.3%           |      |             |
|       | Labetalol | 8177            | 3.9%           |      |             | 8177             | 3.9%           |      |             |
|       | Total     | 65,393          |                 |      |             | 211,322           |                |      |             |
| AAC   | Methyldopa | 4528            | 100            | 10   | 1.0%        | 107,321           | 100            | 10   | 3.7%        |

* ARB: Angiotensin receptor blockers, CCB: calcium channel blocker, ACEi: angiotensin-converting enzyme inhibitor, BB: beta-blocker, DU: Diuretic, AAP, AAC and ST are not conventional abbreviations. AAC will involve centrally acting drugs like methyldopa

* Amiloride + HCT was ranked #7 but removed as it is a combination product

**Use by product type**

The use of generic products (across all single and combination class products) dominated in Nigeria (78.4%) but they were less often used in Ghana (21.6%; data not shown).

The use of generic products for the five main classes of single products dominated in Nigeria (average 94.3%) but they were less often used in Ghana (average 30.8%). The proportional use of generic ARBs was 90.3% in Nigeria but only 24.5% in Ghana—a difference of almost four-fold; the proportional use of diuretics in Nigeria (88.1%) was nine times that of Ghana (9.6%, Table 4). The use of CCB in Nigeria was almost exclusively generic (97.9%) but lower in Ghana (59.4%). In four classes—BB, ARB, ACEi, and diuretics—the use of originator brands prevailed in Ghana whereas the use of generic products dominated in all five classes in Nigeria (Table 4).
most used medicines in Ghana were candesartan, nifedipine, lisinopril, amlodipine, and losartan accounting for 79% of the top ten medicines. The five most used products in Ghana were candesartan 16 mg, nifedipine 30 mg, amlodipine 5 mg, candesartan 8 mg, and losartan 50 mg. The most used medicine class in Nigeria was ARB followed by CCB, then diuretics. The five most used medicines were losartan, lisinopril, nifedipine, furosemide, and amlodipine accounting for 74% of the top ten medicines. In Nigeria the top five products were furosemide 40 mg, amlodipine 5 mg, losartan 50 mg, nifedipine 30 mg, and lisinopril 10 mg. More generic products were used in Nigeria than Ghana. AHM use was broadly similar for both countries—ARB and CCB were the first and second most used medicines, but the third for Ghana was ACEi while for Nigeria it was diuretics. This difference may be attributed to the high cost of ACEi in Nigeria which makes it more difficult to afford, despite its proven advantages in terms of lowering blood pressure over diuretics [19].

A recent economic evaluation and budget impact analysis on the main antihypertensive therapeutic groups used for uncomplicated essential hypertension in a Ghanaian population [20] found that diuretics were more cost-effective than ACEi, ARB, or BB for first-line management of essential hypertension; this result was driven by the greater reduction in stroke incidence with diuretics. CCB were more effective than diuretics but were

Table 3 Use of antihypertensive medicines by dose product: use in defined daily dose [DDD] and proportion within all single-medicine dose products [%] in Ghana and Nigeria

| No | Ghana Medicine | Dose (mg) | Use (DDD) | % all use | Nigeria Medicine | Dose (mg) | Use (DDD) | % all use |
|----|----------------|-----------|-----------|-----------|-----------------|-----------|-----------|-----------|
| 1  | Candesartan    | 16        | 153,812   | 16        | Furosemide      | 40        | 397,284   | 12.2      |
| 2  | Nifedipine     | 30        | 119,532   | 12.4      | Amlodipine      | 5         | 394,230   | 12.1      |
| 3  | Amlodipine     | 5         | 101,778   | 10.6      | Losartan        | 50        | 271,533   | 8.3       |
| 4  | Candesartan    | 8         | 83,653    | 8.7       | Nifedipine      | 30        | 265,585   | 8.2       |
| 5  | Losartan       | 50        | 75,340    | 7.8       | Lisinopril      | 10        | 234,870   | 7.2       |
| 6  | Lisinopril     | 10        | 72,950    | 7.6       | Losartan        | 100       | 194,982   | 6         |
| 7  | Indapamide     | 1.5       | 65,332    | 6.8       | Lisinopril      | 20        | 149,234   | 4.6       |
| 8  | Nifedipine     | 20        | 38,309    | 4         | HCT             | 50        | 148,244   | 4.6       |
| 9  | Lisinopril     | 20        | 37,944    | 3.9       | Nifedipine      | 20        | 142,915   | 4.4       |
| 10 | Atenolol       | 50        | 26,014    | 2.7       | Valsartan       | 160       | 128,352   | 3.9       |
| 11 | Candesartan    | 32        | 23,096    | 2.4       | Valsartan       | 80        | 111,478   | 3.4       |
| 12 | Lisinopril     | 5         | 18,110    | 1.9       | Methyldopa      | 250       | 107,321   | 3.3       |
| 13 | Valsartan      | 160       | 17,784    | 1.8       | Telmisartan     | 80        | 92,180    | 2.8       |
| 14 | Losartan       | 100       | 17,044    | 1.8       | Indapamide      | 1.5       | 74,382    | 2.3       |
| 15 | Valsartan      | 80        | 7720      | 0.8       | Atenolol        | 50        | 73,747    | 2.3       |
| 16 | Nifedipine     | 10        | 2648      | 0.3       | Telmisartan     | 40        | 55,627    | 1.7       |
| 17 | Methyldopa     | 500       | 2345      | 0.2       | Losartan        | 25        | 51,395    | 1.6       |
| 18 | Methyldopa     | 250       | 2184      | 0.2       | Lisinopril      | 5         | 33,969    | 1         |
| 19 | Furosemide     | 40        | 1951      | 0.2       | Atenolol        | 100       | 31,380    | 1         |
| 20 | Valsartan      | 320       | 1580      | 0.2       | Candesartan     | 16        | 21,002    | 0.6       |
| 21 | Atenolol       | 100       | 795       | 0.1       | Atenolol        | 25        | 16,429    | 0.5       |
| 22 | Furosemide     | 20        | 17        | 0         | Candesartan     | 8         | 12,201    | 0.4       |
| 23 | Atenolol       | 25        | 1         | 0         | Furosemide      | 20        | 1648      | 0.1       |
| 24 | Losartan       | 25        | –         | 0         | Amlodipine      | 2.5       | 501       | 0         |
| 25 | Amlodipine     | 2.5       | –         | 0         | Valsartan       | 320       | –         | 0         |
| 26 | HCT            | 50        | –         | 0         | Nifedipine      | 10        | –         | 0         |
| 27 | Telmisartan    | 80        | –         | 0         | Methyldopa      | 500       | –         | 0         |
| 28 | Telmisartan    | 40        | –         | 0         | Candesartan     | 32        | –         | 0         |
| Total |             | 962,650   |           | 80.5      | Total           | 3,252,329 |           | 71.6      |

HCT hydrochlorothiazide
associated with higher costs. Nevertheless, both thiazide diuretics and CCB were regarded as cost-effective treatment options in Ghana, consistent with evidence also available from Nigeria [21]. Notably the 2017 Ghanaian Standard Treatment Guidelines stipulate a preference for TZDs and CCBs, and recommends against the use of ACEi as first line drugs for uncomplicated hypertension in black patients [22]. Despite these recommendations, we found that the most used medicine class in Ghana was ARB followed by CCB and ACEi. Data from the NHIS showed that CCB, followed by diuretics, are the most predominantly used in public health facilities in Ghana [23]. When choosing antihypertensive drug treatment for adults of black African or African-Caribbean family origin, the National Institute of Health and Care Excellence (NICE) in the UK says to consider an ARB, in preference to an ACE inhibitor [24].

The discordance between guidelines and practice may reflect, in part, that guidelines can be slow to influence practice if not supported by an active implementation strategy. The previous Ghanaian guidelines (2010) did not indicate any clinically-informed medicine preferences for managing uncomplicated essential hypertension, leaving the choice of first-line treatment open for the five main classes of AHM. In addition, the Ghanaian NHIS did not provide incentives to encourage the use of lower-priced formulations or better-value AHM classes. This appears to be an ongoing issue, given the relatively low levels of generic AHM use revealed in our study. The higher level of use of originator products may reflect prescriber and or patient preferences for these products perhaps linked to delayed NHIS reimbursement to providers, thus encouraging out-of-pocket expenditure, or related to concerns about quality [25]. In addition, it may also highlight the need for strengthened reimbursement and procurement policies—informed by health technology assessment (HTA)—to help ensure medicine costs better reflect their ‘value-based’ price. In that regard the recently launched Ghana Strategy for Health Technology Assessment (2020) sees HTA as a strategic instrument to inform the selection, pricing and procurement of pharmaceuticals as well as other health technologies, at least for the publicly-funded sector [26].

The use of combination products was tenfold lower in Ghana than Nigeria. Clinically, combination treatment may be preferred when existing monotherapy is not achieving adequate control and there is a reluctance to increase doses because of the risk of side effects [27]. It is not clear why the use of combination products were higher in Nigeria but some factors would likely be the availability of such products, out-of-pocket costs, patient and prescriber preferences, and the local epidemiology of hypertension. This warrants further investigation.

This is one of the first studies that we know of to report on the use of AHM at the community level in Ghana and Nigeria using a novel data source. We acknowledge three main limitations of our approach. Firstly, the data are extracted from a commercial source, which was not...
designed for research purposes so there may be some elements that are not available for analysis. Secondly, we do not have an adequate population denominator to ascertain absolute quantities of medicines use as per the DDD metric [18]. Thirdly, these are aggregated data and we cannot ascertain the indications for use as these AHM can be used to treat several CVD conditions nor the likely concomitant use of single AHM products at the same time.

Studies of AHM use in Nigeria have been inconsistent; most studies showed that CCBs, diuretics and BB are the most used AHM [28–31] but one study showed a preference for ACEIs, either as single or combination products [32]. The former three studies were based in single hospitals with few participants, whereas the latter study [32] was community-based with a large sample size that likely captures the AHM use irrespective of where they received their prescriptions (e.g., hospital, clinic). The use of particular AHM classes may be attributed to cost, prescriber’s preference, a reluctance to change medication, and perceived advantages of each class.

The use of combination AHM products is more common in Nigeria than Ghana. This observation is supported by other studies that show Nigerians prefer combination therapy; most study participants used combination therapy but only less than 20% [28], 5% [29] and 13% [32] of the study participants used monotherapy. The concomitant use of single AHM products can reduce the burden of adverse reactions of a single AHM used in high doses, in reducing cases of drug resistance, and in gaining better blood pressure control, although the cost might be higher and adherence more difficult. It also conforms to recommendations from the American Heart Association [23] and to the recently revised Nigerian National Standard Treatment Guidelines [33]. Recent Nigerian studies have shown low adherence to concomitant use of single AHM products (1% [34], 4.1% [35], 8.9% [36], and 31.8% [37]) and this is consistent with a study that compared AHM adherence in Nigeria and Ghana [38]. On the contrary, adherence to AHM was found to be high in a Ghanaian study (89.2%, but not stated if fixed dose combination or concomitant single products) [39] and as reported by stakeholders in a qualitative study [40]. We emphasise the need for tailored adherence education and counselling for patients using concomitant AHM.

Nigerians use more generic products in the community whereas Ghanaians prefer originator products; consistent with other studies [41–43]. In Nigeria, the guidelines [22] and the essential medicine lists [44] contain only generic names, as does the Ghanaian NHIS medicine list [45]. In both Ghana and Nigeria, originator products are more expensive than generic products as they are imported [46]. Furthermore, there may be a wide range of costs for generic products in low and middle income countries (LMIC) which may be even more expensive than in higher income countries. People in LMIC disproportionately buy expensive branded generic medicines rather than cheaper unbranded medicines [47]. Although there are good reasons to support the local production of generic (i.e. off-patent) medicines [48], some prescribers and patients might trust originator products more [49].

The use of generic products reduced expenditure and out-of-pocket payments by hypertensive patients without affecting medicine utilisation [50]. This might also explain the dominance of generic use in Nigeria due to patient preference: the out-of-pocket payment for healthcare was 71.5% in Nigeria (based on national health accounts [51]) but only 40% in Ghana [52]. The AHM use in Ghana is broadly consistent with two other recent studies from Ghana using claims data from the NHIS (where CCB were the most widely used, preferred additional treatment was a diuretic) [23] and private health insurance companies [53].

Both countries adhered to the guidelines for the treatment of hypertension; they are using CCB, diuretics, ACEI, ARB, and BB medicines. The Ghana STG are not directive on class; any of the five classes of major antihypertensive drugs can be used as first-line treatment [22]. The Nigerian STG on the other hand stipulates the class of the first line medicines and the subsequent lines of medicines to be used [33]. The differences in selecting a particular AHM from the various classes may be largely due to prescriber preference and availability. The patterns of AHM use in Ghana are not consistent with the economic evaluation of AHM showing that DU are more cost-effective than CCB [20]. HTA can help to reduce costs within national or jurisdiction-based health insurance systems within the context of universal health coverage [54, 55].

We have revealed some interesting differences in AHM use in Ghana and Nigeria over five years. In future, it would be beneficial to examine AHM use over time to better understand how guidelines, for example, may influence prescriber preferences and medicines within a class. The economic evaluation of AHM in Ghana [20] could be replicated in Nigeria to better inform medicine use. We could also use data on medicines use to calculate potential savings (and overspend) given the patterns of AHM and the cost-effectiveness of particular AHM classes. Patient level data (e.g. from mPharma and NHIS) can provide powerful insights into the rational—or otherwise—use of medicines.
Conclusions

The differences between AHM use in Ghana and Nigeria may result from a combination of medical, contextual and policy evidence [56–58] and reflect factors related to clinical guidance (e.g. standard treatment guidelines), accessibility to prescribers and the role of community pharmacies, and structure of the health system and universal health coverage including public funding for medicines. We show the feasibility of using novel data sources to gain insights on medicines use in the community.

Acknowledgements

We acknowledge initial contributions from Jonathan Zobi and Yaa Owusu-Agyeman at mPharma.

Author contributions

SH and ET designed the study. ET obtained the data and SH analysed the data. SH and ET developed the manuscript. DA, BSCU, CO and FR interpreted the data and provided expert advice on clinical aspects and health systems. All authors read, revised, and approved the paper before its final submission.

Funding

This study received no specific funding and was funded from existing salaries. FR is supported by the International Development Support Initiative, which is funded by the Bill and Melinda Gates Foundation (OPP1202541).

Availability of data and materials

The data that support the findings of this study are available from mPharma but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the corresponding author upon reasonable request and with permission of mPharma.

Declarations

Ethics approval and consent to participate

This study was granted exemption from ethics review by the University of Queensland, Australia (Ref no 2020000453, 4 March 2020). The research uses only existing collections of data that contain only non-identifiable data and is of negligible risk. Administrative permissions were required from mPharma to access the extracted aggregated data from mPharma. The parties (SH, University of Queensland) and mPharma (ET) signed a non-disclosure agreement to access the extracted aggregated data from mPharma. The parties (SH, University of Queensland) and mPharma (ET) signed a non-disclosure agreement with permission of mPharma.

Consent for publication

Not applicable.

Competing interests

ET was an employee of mPharma between 2019 and 2021. The remaining authors declared that they do not have any conflicts of interest.

Author details

1School of Pharmacy, The University of Queensland, 20 Cornwall St, Woolloongabba, QLD 4102, Australia. 2Faculty of Pharmacy and Pharmaceutical Sciences, KwaZuNkwa University of Science and Technology, Kumasi, Ghana. 3Department of Pharmacy, Korle Bu Teaching Hospital, Accra, Ghana. 4Department of Community Medicine, College of Medicine, University of Nigeria, Enugu, Nigeria. 5International Decision Support Initiative, London School of Hygiene and Tropical Medicine, London, UK. 6Seattle, USA.

Received: 10 March 2022 Accepted: 19 May 2022 Published online: 10 August 2022

References

1. World Health Organization. Noncommunicable diseases progress monitor 2020. Geneva: WHO, 2020.
2. World Health Organization. Noncommunicable diseases country profiles 2018. Geneva: WHO, 2018.
3. World Health Organization. Noncommunicable diseases. Key facts. Geneva, WHO, 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases.
4. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.
5. Fisher NDL, Curfman G. Hypertension-A public health challenge of global proportions. JAMA. 2018;320(17):1757–9.
6. Unger T, Borghi C, Charcarh F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension. 2020;76(6):1334–57.
7. Nulu S, Aronow WS, Frishman WH. Hypertension in sub-Saharan Africa: a contextual view of patterns of disease, best management, and systems issues. Cardiol Rev. 2016;24(1):30–40.
8. Adoloye D, Basquill C, Aderemi AV, Thompson JY, Obi FA. An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. J Hypertens. 2015;33(2):230–42.
9. Ogah OS, Okpechi I, Chukwuonye EI, Akinyemi JO, Omwubure BJ, Falase AO, et al. Blood pressure, prevalence of hypertension and hypertension related complications in Nigerian Africans: a review. World J Cardiol. 2012;4(12):527–40.
10. Odili AN, Chori BS, Danladi B, Nwakile PC, Okoye IC, Abdullahi U, et al. Prevalence, awareness, treatment and control of hypertension in Nigeria: data from a nationwide survey. Glob Health. 2020;15(1):47.
11. Bosu WK, Bosu DK. Prevalence, awareness and control of hypertension in Ghana: a systematic review and meta-analysis. PLoS ONE. 2021;16(3):e0248137.
12. Basu S, Wagner RG, Sewpaul R, Reddy P, Davies J. Implications of scaling up cardiovascular disease treatment in South Africa: a microsimulation and cost-effectiveness analysis. Lancet Glob Health. 2019;7(2):e270–80.
13. Abubakar J, Obasa S. An estimate of average cost of hypertension and its catastrophic effect on the people living with hypertension: patients’ perception from two hospitals in Abuja, Nigeria. Int J Soc Sci Econ Rev. 2020;2(2):10–9.
14. Chalkidou K, Claxton K, Silverman R, Yadav P. Value-based tiered pricing for universal health coverage: an idea worth revisiting. Gates Open Res. 2020;4:16.
15. Atinyi R, Takramah W, Axame WK, Owusu R, Parbey PA, Takase M, et al. Prevalence and awareness of hypertension among urban and rural adults in the Keta municipality, Ghana. J Med Res. 2017;3(3):155–63.
16. Sarfo FS, Mobula LM, Burnham G, Ansong D, Plange-Rhule J, Sarfo-Kantanka O, et al. Factors associated with uncontrolled blood pressure among Ghanaians: evidence from a multicenter hospital-based study. PLoS ONE. 2018;13(3):e0219349.
17. Agyemang C, Nyaaba G, Beune E, Meeks K, Owusu-Dabo E, Addo J, et al. Variations in hypertension awareness, treatment, and control among Ghanaian migrants living in Amsterdam, Berlin, London, and nonmigrant Ghanaians living in rural and urban Ghana—the RODAM study. J Hypertens. 2018;36(1):169–77.
18. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. 2020. https://www.whocc.no/atc_ddd_index/. Accessed 9 Feb 2022.
19. Reisin E, Graves JW, Yamal JM, Barzilay JI, Pressel SL, Einhorn PT, et al. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. J Hypertens. 2014;32(7):1503–13 (discussion 13).
20. Gad M, Lord J, Chalkidou K, Asare B, Lutterodt MG, Ruiz F. Supporting the development of evidence-informed policy options: an economic evaluation of hypertension management in Ghana. Value Health J Int Soc Pharmacoecon Outcomes Res. 2020;23(2):171–9.
21. Ekunwine OL, Okafor CE, Ezenduka CC, Udogaranya PO. Cost–utility analysis of antihypertensive medications in Nigeria: a decision analysis. Cost Eff Resour Alloc C.E. 2013;11(1):2.
22. Ministry of Health Republic of Ghana. Standard treatment guidelines. 7th ed. Accra: Ministry of Health; 2017.

23. Donnyeyong MM, Chang TJ, Pottegård A, Ankrah D, Asero-Boadi F, Addo-Cobbla V, et al. Prevalence and quality of antihypertensive therapy among hypertensive patients enrolled in the Ghana National Health Insurance Scheme. Pharmacoepidemiol Drug Saf. 2021;30(11):1566–75.

24. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE Guideline (NG136) London: NICE; 2019. Available from: https://www.nice.org.uk/guidance/ng136/chapter/Recommendations#treating-and-monitoring-hypertension.

25. Koduah A, Nonvignon J, Kolson A, Kubi S, Morton A, van der Meer R, et al. Health systems, population and patient challenges for achieving universal health coverage for hypertension in Ghana. Health Policy Plan. 2021;36(9):1451–8.

26. Ministry of Health Republic of Ghana. Ghana strategy for health technology assessment. In: Technical Coordination Directorate PD, 1st edn. HTA Secretariat, editor. Accra: MoH; 2020.

27. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of hypertension. EMA Committee for Medicinal Products for Human Use; 2016.

28. Adejumọ O, Okaọa E, Iyave I. Prescription pattern of antihypertensive medications and blood pressure control among hypertensive outpatients at the University of Benin Teaching Hospital in Benin City, Nigeria. Malawi Med J J Med Assoc Malawi. 2017;29(2):113–7.

29. Bakare OQ, Akinwinya MR, Goodman O, Kuyinu YA, Knight OD, Adeniran A, et al. Antihypertensive use, prescription patterns, and cost of medications in a Teaching Hospital in Lagos, Nigeria. Niger J Clin Pract. 2016;19(5):668–72.

30. Ojji DB, Ajayi SO, Mamven MH, Alfa J, Albertino D. Pattern of prescription of anti-hypertensive medications in a tertiary health care facility in Abuja, Nigeria. Ethn Dis. 2013;23(4):480–3.

31. Olarewaju TO, Aderibigbe A, Busari OA, Sanya EO. Antihypertensive drug utilization and conformity to guidelines in a sub-Saharan African hypertensive population. Int J Clin Pharmacol Ther. 2010;48(1):68–75.

32. Mjiniyawa Muhammad S, Yusuf MS, Mohammed H, Sadu H, Suleman BA, Uloko AE. Choice of antihypertensive medications among physicians and its impact on blood pressure control among Nigerians living with hypertension. Niger J Med J Natl Assoc Resid Dr Nigeria. 2016;25(3):220–5.

33. Federal Ministry of Health Nigeria. Standard treatment guidelines Nigeria, 2nd edn. 2017. https://www.medbox.org/document/nigeria-standard-treatment-guidelines#GO. Accessed 23 Sept 2020.

34. Olouvoe EO, Osiboquin O, Adegoke O, Adejimi AA, Adebowale AM, Osibogun A. Medication adherence and patient satisfaction among hypertensive patients attending outpatient clinic in Lagos University Teaching Hospital, Nigeria. Niger Postgrad Med J. 2019;26(2):129–37.

35. Adeoye AM, Adebowale OA, Adeyemo WM, Owoabi MO. Medication adherence and 24-h blood pressure in apparently uncontrolled hypertensive Nigeria patients. Niger Postgrad Med J. 2019;26(1):18–24.

36. Adisa R, Ilesanmi OA, Fakeye TO. Treatment adherence and blood pressure outcome among hypertensive out-patients in two tertiary hospitals in Sokoto, Northwestern Nigeria. BMC Cardiovasc Disord. 2018;18(1):194.

37. Okwuonu CD, Uwanoruci NV, Chimeme OJ, Ogah OS, Mbasano AU, Odigwe CO. Adherence to antihypertensive medication and its correlates among individuals with hypertension in a semi-urban community of Southern Nigeria. J Med Biomed Res. 2015;14(1):5–17.

38. Boina V, Ademola AO, Odusola AO, Ayegbem F, Nwafor CE, Cole H, et al. Factors associated with medication nonadherence among hypertensives in Ghana and Nigeria. Int J Hypertens. 2015;2015:205716.

39. Sarkodie E, Afriyie DK, Hutton-Nyameya A, Ampounsah SK. Adherence to drug therapy among hypertensive patients attending two district hospitals in Ghana. Afr J Health Sci. 2020;20(3):1355–67.

40. Laar AK, Adler AJ, Kotoh AM, Legido-Quigley H, Lange L, Perel P, et al. Health system challenges to hypertension and related non-communicable diseases prevention and treatment: perspectives from Ghanaian stakeholders. BMC Health Serv Res. 2019;19(1):693.

41. Bisiriyu AM, Oyetunde O, Ayenina FA. Intern physicians’ views of generic medicines in a teaching hospital in Southwest Nigeria. Niger J Pharm Res. 2018;14(2):203–10.

42. Fadare JO, Adeoti AO, Desalu OO, Enwere OO, Makusidi AM, Ogunleye O, et al. The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians. Expert Rev Pharmacoecon Outcomes Res. 2016;16(5):639–50.

43. Sarfo F, Mobula L, Arthur L, Plange-Rhule J, Burnham G, Sablah J, et al. Differential pricing of medicines to improve access to medicines for hypertension and diabetes control in Ghana: The Ghana Access and Affordability Program, a multi-center prospective trial [version 1; peer review: 2 not approved]. Gates Open Research. 2019;3:1515.

44. Ministry of Health Republic of Ghana. Essential medicines list. 7th ed. Accra: MoH; 2017.

45. National Health Insurance Scheme. NHS medicines list. 2021. Available from: http://www.nhisp.gov.mw/medlist.aspx.

46. Osafo NG, Ukwu CV, Okonta M. Evaluation of availability, price, and affordability of cardiovascular, diabetes, and global medicines in Abuja, Nigeria. PLoS ONE. 2021;16(8):e0255567.

47. Silverman R, Keller J, Glassman AC, Chalkidou K. Tackling the triple transition in global health procurement. Linked Immunisation Action Network. 2019.

48. Fatokun O. Fostering local production of essential medicines in Nigeria. Bull World Health Organ. 2020;98(7):507–8.

49. Hamill H, Hampshire K, Mairiwah S, Amoako-Sakyi D, Kyei A, Castelli M. Managing uncertainty in medicine quality in Ghana: the cognitive and affective basis of trust in a high-risk, low-regulation context. Soc Sci Med. 2019;234:112369.

50. de Jager H, Suleman F. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa. Int J Clin Pharm. 2019;41(1):81–7.

51. Federal Ministry of Health Nigeria. National health accounts. 2017. Available from: https://www.health.gov.ng/doc/FINAL-VERSION-NHA-2017.pdf.

52. Akwemong P, Akins M, Wyss K, Salari P, Tediosi F. Insured clients out-of-pocket payments for health care under the national health insurance scheme in Ghana. BMC Health Serv Res. 2021;21(1):440.

53. Marfo AF, Marfo JS, Plange-Rhule J, Hollingsworth S. Trends in antihypertensive use in Ghana. J Hypertension. 2022. Submitted.

54. Hollingsworth S, Gyansa-Lutterodt M, Dsane-Selby L, Nonvignon J, Lopert R, Gad M, et al. Implementing health technology assessment in Ghana to support universal health coverage: building relationships that focus on people, policy, and process. Int J Technol Assess Health Care. 2020;36(1):8–11.

55. Uzochukwu BSC, Okeke C, O’Brien N, Ruiz F, Sombie J, Hollingsworth S. Health technology assessment and priority setting for universal health coverage: a qualitative study of stakeholders’ capacity, needs, policy areas of demand and perspectives in Nigeria. Glob Health. 2020;16(1):58.

56. De Maeseneer JM, van Driel ML, Green LA, van Weel C. Medicinal products in the treatment of hypertension. EMA Committee for Medicinal Products for Human Use; 2016.

57. Eek E, van Driel M, Falk M, van Weel C. Antidepressant use and demand in primary care: a review of demand and perspectives in a high-income country. Int J Technol Assess Health Care. 2010;26(4):394–400.

58. Silverman R, Keller J, Glassman AC, Chalkidou K. Tackling the triple transition in global health procurement. Linked Immunisation Action Network. 2019.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.